Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II exploratory trial of TM5614 for COVID-19 pneumonia
jRCT2021200018Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TM5614 in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Deterioration of oxygenation requiring ventilator management. Started Oct 2020; status: completed.
02
Drugs
TM5614
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on jRCT2021200018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200018.